Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14821759 | 0.92 | CA2 (0.41) | CA2CA1TMPRSS15SMN1; SMN2HTT | |
| SCHEMBL14821498 | 0.92 | TMPRSS15 (0.44) | CA2CA1TMPRSS15SMN1; SMN2HTT | |
| SCHEMBL14821760 | 0.91 | CA2 (0.40) | CA2CA1TMPRSS15KMT2APRSS1 | |
| SCHEMBL14821755 | 0.90 | ITGB3 (0.41) | CA2CA1TMPRSS15KMT2AALDH1A1 | |
| SCHEMBL15948334 | 0.90 | TMPRSS15 (0.45) | CA2CA1TMPRSS15SMN1; SMN2HTT | |
| SCHEMBL14821750 | 0.85 | CA2 (0.39) | CA2CA1TMPRSS15KMT2APRSS1 | |
| SCHEMBL14821124 | 0.85 | SMN1; SMN2 (0.46) | TMPRSS15SMN1; SMN2HTTKMT2AALDH1A1 | |
| SCHEMBL14821506 | 0.84 | TMPRSS15 (0.45) | CA2CA1TMPRSS15KMT2APRSS1 | |
| SCHEMBL15948342 | 0.83 | TMPRSS15 (0.44) | CA2CA1TMPRSS15SMN1; SMN2HTT | |
| SCHEMBL14821754 | 0.83 | CA2 (0.40) | CA2CA1TMPRSS15KMT2APRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | CA2 513/4885CA1 1291/4885TMPRSS15 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.